Coherus Biosciences logo

Coherus Biosciences Share Price Today

(NASDAQ: CHRS)

Coherus Biosciences share price is $0.91 & ₹78.73 as on 20 Mar 2025, 2.30 'hrs' IST

$0.91

0.02

(2.23%)

Market is closed - opens 7 PM, 20 Mar 2025

View live Coherus Biosciences share price in Dollar and Rupees. Guide to invest in Coherus Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Coherus Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Coherus Biosciences share price movements

  • Today's Low: $0.89
    Today's High: $0.95

    Day's Volatility :6.4%

  • 52 Weeks Low: $0.66
    52 Weeks High: $2.64

    52 Weeks Volatility :74.99%

Coherus Biosciences (CHRS) Returns

PeriodCoherus Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-38.7%
-9999999.0%
0.0%
6 Months
-19.71%
-9999999.0%
0.0%
1 Year
-63.42%
-9999999.0%
0.0%
3 Years
-92.54%
-9999999.0%
-15.2%

Coherus Biosciences (CHRS) Key Statistics

in dollars & INR

Previous Close
$0.8875
Open
$0.9
Today's High
$0.9498
Today's Low
$0.889
Market Capitalization
$106.1M
Today's Volume
$1.6M
52 Week High
$2.64
52 Week Low
$0.6603
Revenue TTM
$267.0M
EBITDA
$-99.3M
Earnings Per Share (EPS)
$0.25
PE Ratio
3.55
Profit Margin
10.68%
Quarterly Earnings Growth YOY
-0.75%
Return On Equity TTM
-1657.06%

How to invest in Coherus Biosciences Stock (CHRS) from India?

It is very easy for Indian residents to invest directly in Coherus Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Coherus Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Coherus Biosciences or CHRS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Coherus Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Coherus Biosciences shares which would translate to 0.951 fractional shares of Coherus Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Coherus Biosciences, in just a few clicks!

Returns in Coherus Biosciences (CHRS) for Indian investors in Rupees

The Coherus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Coherus Biosciences investment value today

Current value as on today

₹40,761

Returns

₹59,239

(-59.24%)

Returns from Coherus Biosciences Stock

₹63,306 (-63.31%)

Dollar Returns

₹4,068 (+4.07%)

Indian investors sentiment towards Coherus Biosciences (CHRS)

3%

Period: Feb 17, 2025 to Mar 19, 2025. Change in 30 Days versus previous period

Search interest for Coherus Biosciences Stock from India on INDmoney has increased by 3% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Coherus Biosciences

  • Vanguard Group Inc

    9.63%

  • BlackRock Inc

    9.56%

  • Point72 Asset Management, L.P.

    4.56%

  • Rubric Capital Management LP

    4.54%

  • TANG CAPITAL MANAGEMENT LLC

    3.15%

  • Kohlberg Kravis Roberts & Co LP

    2.62%

Analyst Recommendation on Coherus Biosciences

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Coherus Biosciences(by analysts ranked 0 to 5 stars)

Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Coherus Biosciences Stock (CHRS)

What analysts predicted

Upside of 548.35%

Target:

$5.90

Current:

$0.91

Insights on Coherus Biosciences Stock (Ticker Symbol: CHRS)

  • Price Movement

    In the last 3 months, CHRS stock has moved down by -40.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 70.77M → 54.14M (in $), with an average decrease of 23.5% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -10.75M → -50.69M (in $), with an average decrease of 371.6% per quarter
  • CHRS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.3% return, outperforming this stock by 134.7%
  • CHRS vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 53.4% return, outperforming this stock by 146.6%
  • Price to Sales

    ForCHRS every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.4 for every $1 of sales.

Coherus Biosciences Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences is currently in a neutral trading position according to technical analysis indicators.

Coherus Biosciences (CHRS) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Coherus Biosciences Inc logo
-18.99%
-19.71%
-63.42%
-92.54%
-93.62%
Alnylam Pharmaceuticals, Inc. logo
1.38%
-8.28%
71.25%
56.03%
155.84%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Coherus Biosciences Inc logo
3.55
3.55
0.0
-1.19
-16.57
-0.12
NA
-1.14
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.52
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Coherus Biosciences Inc logo
Buy
$106.1M
-93.62%
3.55
10.68%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.6B
155.84%
NA
-12.37%

About Coherus Biosciences

Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California.
Organization
Coherus Biosciences
Employees
228
CEO
Mr. Dennis M. Lanfear
Industry
Health Technology

Management People of Coherus Biosciences

NameTitle
Mr. Dennis M. Lanfear
Chairman, President & CEO
Mr. Bryan J. McMichael
Chief Financial Officer
Mr. Paul Reider
Chief Commercial Officer
Mr. Richard L. Hameister
Chief Technical Officer
Ms. Jodi Sievers
Vice President of Investor Relations & Corporate Communications
Mr. Andy Rittenberg
Executive Vice President of General Counsel
Mr. Scott Saywell
Executive Vice President of Corporate Development
Ms. Rebecca Sunshine
Chief Human Resources Officer
Mr. Michael Chen
Senior Vice President of Commercial Analytics & Trade
Dr. Theresa M. Lavallee Ph.D.
Chief Development Officer & Chairman of Scientific Advisory Board

Important FAQs about investing in CHRS Stock from India :

What is Coherus Biosciences share price today?

Coherus Biosciences share price today stands at $0.91, Open: $0.90 ; Previous Close: $0.89 ; High: $0.95 ; Low: $0.89 ; 52 Week High: $2.64 ; 52 Week Low: $0.66.

The stock opens at $0.90, after a previous close of $0.89. The stock reached a daily high of $0.95 and a low of $0.89, with a 52-week high of $2.64 and a 52-week low of $0.66.

Can Indians buy Coherus Biosciences shares?

Yes, Indians can invest in the Coherus Biosciences (CHRS) from India.

With INDmoney, you can buy Coherus Biosciences at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Coherus Biosciences at zero transaction cost.

How can I buy Coherus Biosciences shares from India?

It is very easy to buy Coherus Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Coherus Biosciences (CHRS) be purchased?

Yes, you can buy fractional shares of Coherus Biosciences with INDmoney app.

What are the documents required to start investing in Coherus Biosciences stocks?

To start investing in Coherus Biosciences, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Coherus Biosciences Stock (CHRS)?

Today’s highest price of Coherus Biosciences (CHRS) is $0.95.

Today’s lowest price of Coherus Biosciences (CHRS) is $0.89.

What is today's market capitalisation of Coherus Biosciences?

Today's market capitalisation of Coherus Biosciences CHRS is 106.1M

What is the 52 Week High and Low Range of Coherus Biosciences Stock (CHRS)?

  • 52 Week High

    $2.64

  • 52 Week Low

    $0.66

What are the historical returns of Coherus Biosciences (CHRS)?

  • 1 Month Returns

    -18.99%

  • 3 Months Returns

    -19.71%

  • 1 Year Returns

    -63.42%

  • 5 Years Returns

    -93.62%

Who is the Chief Executive Officer (CEO) of Coherus Biosciences ?

Mr. Dennis M. Lanfear is the current Chief Executive Officer (CEO) of Coherus Biosciences.